Accelerating phase III clinical trial enrollment
A pharmaceutical company needed to reevaluate their clinical trial enrollment strategy due to slow patient recruiting at site locations. Using analytic capabilities within Passport Planning and Performance to analyze claims data, the company identified the fastest recruiting sites and investigators, leading to accelerated patient enrollment, $10M in clinical trial cost savings, and FDA approval of the treatment 12 months earlier than anticipated.
savings by accelerating clinical trial enrollment
Insufficient patient volumes from existing recruiting sites was slow and costly
The pharmaceutical company, plagued with slow phase III clinical trial patient recruiting, had only reached 20% patient enrollment within the 24-month goal provided by the FDA. The clinical trial sites previously selected were experiencing insufficient eligible patients because the investigators they had chosen were not enrolling or were slow to enroll patients. This caused delays in the completion timelines of the clinical trials.
Leveraging the analytics in Planning & Performance to identify opportunities to accelerate patient enrollment
Using technology within the Clinical Trial Accelerator module found within Passport Planning & Performance to analyze claims data revealed drivers of speed to patient enrollment. The analysis identified that eighteen of the top twenty sites with eligible patients were not part of the clinical trial. As a result of using the tool a dynamic list was generated that provide a list of investigators, site locations, and physicians who could refer patients to investigators.
Achieving FDA approval 12 month earlier than anticipated while saving $10M in clinical trial costs
The company completed enrollment of the remaining 80% of patients needed for the clinical trial within the next 12 months after implementing a strategy based on identifying opportunities to accelerate patient enrollment. This speed to enrollment saved the pharmaceutical company an estimated $10M in clinical trial costs and it achieved FDA approval 12 months earlier than anticipated.